PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 500 shares, a drop of 89.4% from the August 15th total of 4,700 shares. Based on an average trading volume of 3,700 shares, the days-to-cover ratio is currently 0.1 days.
Institutional Trading of PureTech Health
An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. grew its position in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company's stock after buying an additional 630,000 shares during the period. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. 2.32% of the stock is currently owned by hedge funds and other institutional investors.
Get PureTech Health alerts:PureTech Health Price Performance
NASDAQ PRTC traded up $0.24 during mid-day trading on Thursday, reaching $29.29. 200 shares of the company's stock traded hands, compared to its average volume of 1,478. The company has a fifty day simple moving average of $27.09 and a 200-day simple moving average of $25.12. PureTech Health has a 1-year low of $18.15 and a 1-year high of $54.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.54 and a quick ratio of 2.22.
Wall Street Analyst Weigh In
PRTC has been the topic of a number of recent research reports. Piper Sandler boosted their target price on shares of PureTech Health from $37.00 to $44.00 and gave the stock an "overweight" rating in a research report on Thursday, August 25th. SVB Leerink cut their price objective on shares of PureTech Health from $70.00 to $66.00 and set an "outperform" rating on the stock in a report on Wednesday, June 15th.PureTech Health Company Profile
(Get Rating)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
Featured Articles
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Has 3M Reached the Point of Being so Bad It's Good?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.